ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2447

Disease Activity Is Associated With Development Of Inflammatory Bowel Disease In Ankylosing Spondylitis: 12-Year Results From OASIS

Ivette Essers1,2, Sofia Ramiro3,4, Carmen Stolwijk1,2, Robert Landewé5,6, Désirée van der Heijde7, Filip van Den Bosch8, Maxime Dougados9 and Astrid Van Tubergen1,2, 1School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, 2Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 3Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 4Rheumatology, Hospital Garcia de Orta, Almada, Portugal, 5Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 6Rheumatology, Atrium Medical Center, Heerlen, Netherlands, 7Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 8Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, 9Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS) and extraarticular manifestations

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Ankylosing spondylitis (AS) is associated with extra-articular manifestations (EAMs) such as acute anterior uveitis (AAU), inflammatory bowel disease (IBD), and psoriasis. Little is known about the characteristics of patients who develop any EAM. We aimed to identify characteristics associated with the development of EAMs in a prevalence cohort of patients with AS.

Methods:  Twelve year follow-up data from patients included in the Outcome in AS International Study (OASIS) were used. Additionally, medical charts were checked for the presence of AAU, IBD or psoriasis, by two independent extractors. Baseline demographic, clinical and radiographic characteristics of patients with and without uveitis, IBD or psoriasis were compared. Logistic regression was performed to identify characteristics associated with the presence of any EAM. Furthermore, Cox regression and survival analyses were performed to identify characteristics associated with development of any EAM over time. Analysis were performed with baseline characteristics as well as with time-varying characteristics.

Results:  216 patients were included (mean age 43.6 years (SD 12.7), 154 (71%) men, mean symptom duration 20.5 years (SD 11.7), 174 (85%) HLA-B27 positive and mean follow-up period 8.3 years (SD 4.3)). At baseline, 59 (27%) patients had any EAM, of which 39 (18%) AAU, 15 (7%) IBD, and 9 (4%) psoriasis. Four patients (2%) had more than one EAM. At baseline, patients with AAU compared with patients without AAU were older (49.1 vs 42.4 years, p<0.01), had a longer symptom duration (25.9 vs 19.3 years, p<0.01), and more radiographic damage (modified Stoke AS Spinal Score 16.9 vs 10.6, p=0.03). Patients with psoriasis compared with patients without psoriasis were older (51.3 vs 43.3 years, p=0.05). There were no differences between patients with and without IBD. During follow-up 27 patients developed a new EAM; 19 AAU, 9 IBD, and 5 psoriasis with incidence rates of 0.9%, 0.4%, and 0.02% per year, respectively. The following time-varying characteristics were associated with the development of IBD in univariable analysis: AS Disease Activity Score (HR 2.81, 95%-CI 1.43-5.53), Bath Ankylosing Disease Activity Index (HR 1.47 95%-CI 1.09-1.98), C-reactive protein (HR 1.02, 95%-CI 1.00-1.05) Bath AS Functional index (HR 1.40, 95%-CI 1.09-1.80) and Bath AS Global Score (HR 1.46, 95%-CI 1.10-1.96). CRP was also weakly associated with the development of AAU (HR 1.02, 95%-CI 1.01-1.04) in time-varying analysis. No significant associations with development of psoriasis were found.

Conclusion:  At baseline, a substantial number of patients already had an EAM in this prevalence cohort with relatively long symptom duration. Development of new EAMs was infrequently observed. In particular disease activity, but also physical function and patient global assessment, were associated with development of IBD. CRP was associated with the development of AAU. Characteristics associated with the development of psoriasis were not found.


Disclosure:

I. Essers,
None;

S. Ramiro,
None;

C. Stolwijk,
None;

R. Landewé,
None;

D. van der Heijde,
None;

F. van Den Bosch,

Abbott, MSD, Pfizer, UCB,

5,

Abbott, Bristol-Myers Squibb, MSD, UCB,

8;

M. Dougados,
None;

A. Van Tubergen,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-is-associated-with-development-of-inflammatory-bowel-disease-in-ankylosing-spondylitis-12-year-results-from-oasis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology